Hydroxychloroquine Use and Decreased Risk of Diabetes in Rheumatoid Arthritis Patients
JCR: Journal of Clinical Rheumatology,  Clinical Article

Bili A et al. - The findings support the potential benefit of hydroxychloroquine in attenuating the risk of diabetes in rheumatoid arthritis patients..

Methods
  • Retrospective cohort of 1127 adults with newly diagnosed rheumatoid arthritis and no diabetes within the Geisinger Health System between January 1, 2003, and March 31, 2008.
  • Patients were classified as ever users (n = 333) or never users (n = 794) of hydroxychloroquine.
  • Incident diabetes cases were defined using 2010 American Diabetes Association criteria.

Results
  • The median follow-up times for the ever and never hydroxychloroquine users were 26.0 and 23.0 months, respectively (P = 0.28).
  • The median duration of hydroxychloroquine exposure was 14.0 months.
  • Of the 48 cases developing diabetes during observation, 3 were exposed to hydroxychloroquine at time of development and 45 were nonexposed, yielding incidence rates of 6.2 and 22.0 per 1000 per year (P = 0.03), respectively.
  • In time-varying Cox proportional hazards regression models adjusting for sex, age, body mass index, positive rheumatoid factor and anti-cyclic citrullinated peptide antibodies, erythrocyte sedimentation rate, and nonsteroidal anti-inflammatory drug, glucocorticoid, methotrexate, and tumor necrosis factor (alpha) inhibitor use, the hazard ratio for incident diabetes among hydroxychloroquine users was 0.29 (95% confidence interval, 0.09-0.95; P = 0.04) compared with nonusers.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Endocrinology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Endocrinology Articles

1 Effects of 12 weeks high-dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency – A double-blind, randomized, placebo-controlled trial Metabolism, July 9, 2014    Clinical Article

2 Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis Diabetes Care, October 24, 2014    Clinical Article

3 Seasonal variation in month of diagnosis in children with type 1 diabetes registered in 23 European centers during 1989-2008: little short-term influence of sunshine hours or average temperature Pediatric Diabetes, October 16, 2014    Clinical Article

4 Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator–controlled, adaptive proof-of-concept phase 2 study Diabetes Care, September 19, 2014    Clinical Article

5 Hemoglobin A1c less than 6.5% on admission increases risk for in-hospital and 1-year mortality in patients with diabetes and chest pain Cardiovascular Endocrinology, September 2, 2014    Clinical Article

6 Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study) The American Journal of Cardiology, October 3, 2014    Clinical Article

7 New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, September 22, 2014    Clinical Article

8 The effects of intravenous insulin infusions on early mortality for patients with acute coronary syndromes who present with hyperglycaemia: A matched propensity analysis using data from the MINAP database 2008–2012 European Heart Journal: Acute Cardiovascular Care, October 1, 2014    Clinical Article

9 Latent autoimmune diabetes in adults with low-titer GAD antibodies: Similar disease progression with type 2 diabetes: A nationwide, multicenter prospective study (LADA China Study 3) Diabetes Care, October 24, 2014    Clinical Article

10 Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus The Journal of Clinical Pharmacology, October 20, 2014    Clinical Article

11 Effects of 12 weeks treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study European Journal of Endocrinology, October 13, 2014    Clinical Article

12 Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin Acta Diabetologica, October 15, 2014    Clinical Article

13 Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: The LIBRA Trial Diabetes Care, September 26, 2014    Clinical Article

14 Initial combination of linagliptin and metformin compared with linagliptin monotherapy in newly diagnosed type 2 diabetes patients with marked hyperglycaemia: a randomised, double-blind, active-controlled, parallel group, multinational clinical trial Diabetes, Obesity and Metabolism, October 10, 2014    Clinical Article

15 New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, September 12, 2014    Clinical Article

16 The pharmacokinetics of metformin and concentrations of HbA1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus British Journal of Clinical Pharmacology, October 9, 2014    Clinical Article

17 An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes Diabetes Care, September 12, 2014    Clinical Article

18 New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, October 23, 2014    Clinical Article

19 The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus Canadian Journal of Diabetes, October 28, 2014    Review Article

20 Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus The Journal of Clinical Hypertension, October 24, 2014    Clinical Article

Indexed Journals in Endocrinology: Endocrinology, Journal of Endocrinology, Clinical Endocrinology, Diabetesmore